Non-dopaminergic Treatments for Motor Control in Parkinson's DiseaseFOX, Susan H.Drugs (Basel). 2013, Vol 73, Num 13, pp 1405-1415, issn 0012-6667, 11 p.Article

Medication-related impulse control and repetitive behaviors in parkinson diseaseVOON, Valerie; FOX, Susan H.Archives of neurology (Chicago). 2007, Vol 64, Num 8, pp 1089-1096, issn 0003-9942, 8 p.Article

The serotonergic system in motor and non-motor manifestations of Parkinson's diseaseHUOT, Philippe; FOX, Susan H.Experimental brain research. 2013, Vol 230, Num 4, pp 463-476, issn 0014-4819, 14 p.Article

Serotonin and Parkinson's Disease: On Movement, Mood, and MadnessFOX, Susan H; CHUANG, Rosalind; BROTCHIE, Jonathan M et al.Movement disorders. 2009, Vol 24, Num 9, pp 1255-1266, issn 0885-3185, 12 p.Article

Evidence Based MedicineSAMPAIO, Cristina; SEPPI, Klaus; FOX, Susan H et al.Movement disorders. 2011, Vol 26, Num 12, issn 0885-3185, 81 p., SUPSerial Issue

5-HT_2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's diseaseFOX, Susan H; BROTCHIE, Jonathan M.Movement disorders. 2000, Vol 15, Num 6, pp 1064-1069, issn 0885-3185Article

A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating ScaleFOX, Susan H; JOHNSTON, Tom H; QIN LI et al.Movement disorders. 2012, Vol 27, Num 11, pp 1373-1378, issn 0885-3185, 6 p.Article

Effect of Histamine H₂ Receptor Antagonism on Levodopa-Induced Dyskinesia in the MPTP-Macaque Model of Parkinson's DiseaseJOHNSTON, Tom H; VAN DER MEIJ, Anne; BROTCHIE, Jonathan M et al.Movement disorders. 2010, Vol 25, Num 10, pp 1379-1390, issn 0885-3185, 12 p.Article

The α₂ Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian PrimatesJOHNSTON, Tom H; FOX, Susan H; PIGGOTT, Matthew J et al.Movement disorders. 2010, Vol 25, Num 13, pp 2084-2093, issn 0885-3185, 10 p.Article

Factors associated with dopaminergic drug-related pathological gambling in parkinson diseaseVOON, Valerie; THOMSEN, Teri; MIYASAKI, Janis M et al.Archives of neurology (Chicago). 2007, Vol 64, Num 2, pp 212-216, issn 0003-9942, 5 p.Article

Overview of the Extranigral Aspects of Parkinson DiseaseLIM, Shen-Yang; FOX, Susan H; LANG, Anthony E et al.Archives of neurology (Chicago). 2009, Vol 66, Num 2, pp 167-172, issn 0003-9942, 6 p.Article

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies : Keys to success and roads to failureFOX, Susan H; LANG, Anthony E; BROTCHIE, Jonathan M et al.Movement disorders. 2006, Vol 21, Num 10, pp 1578-1594, issn 0885-3185, 17 p.Article

Pure cerebello-olivary degeneration of Marie, Foix, and Alajouanine presenting with progressive cerebellar ataxia, cognitive decline, and choreaFOX, Susan H; NIEVES, Anette; BERGERON, Catherine et al.Movement disorders. 2003, Vol 18, Num 12, pp 1550-1554, issn 0885-3185, 5 p.Article

Increased Levels of 5-HT_1A Receptor Binding in Ventral Visual Pathways in Parkinson's DiseaseHUOT, Philippe; JOHNSTON, Tom H; VISANJI, Naomi P et al.Movement disorders. 2012, Vol 27, Num 6, pp 735-742, issn 0885-3185, 8 p.Article

A 10 year retrospective audit of long-term apomorphine use in Parkinson's diseaseTYNE, Hilary L; PARSONS, Jan; SINNOTT, Ann et al.Journal of neurology. 2004, Vol 251, Num 11, pp 1370-1374, issn 0340-5354, 5 p.Article

Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystoniaFOX, Susan H; KELLETT, Mark; MOORE, A. Peter et al.Movement disorders. 2002, Vol 17, Num 1, pp 145-149, issn 0885-3185Article

Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha₂ adrenoceptor antagonist idazoxanFOX, Susan H; HENRY, Brian; HILL, Micheal P et al.Movement disorders. 2001, Vol 16, Num 4, pp 642-650, issn 0885-3185Article

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's DiseaseSEPPI, Klaus; WEINTRAUB, Daniel; SAMPAIO, Cristina et al.Movement disorders. 2011, Vol 26, Num 12, issn 0885-3185, S42-S80, SUPArticle

Striatal histone modifications in models of levodopa-induced dyskinesiaNICHOLAS, Anthony P; LUBIN, Farah D; STANDAERT, David G et al.Journal of neurochemistry. 2008, Vol 106, Num 1, pp 486-494, issn 0022-3042, 9 p.Article

Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's diseaseHENRY, Brian; DUTY, Susan; FOX, Susan H et al.Experimental neurology (Print). 2003, Vol 183, Num 2, pp 458-468, issn 0014-4886, 11 p.Article

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's DiseaseFOX, Susan H; KATZENSCHLAGER, Regina; LIM, Shen-Yang et al.Movement disorders. 2011, Vol 26, Num 12, issn 0885-3185, S2-S41, SUPArticle

Ipratropium Bromide Spray as Treatment for Sialorrhea in Parkinson's DiseaseTHOMSEN, Teri R; GALPEM, Wendy R; ASANTE, Abena et al.Movement disorders. 2007, Vol 22, Num 15, pp 2268-2273, issn 0885-3185, 6 p.Article

The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaquesKOPRICH, James B; HUOT, Philippe; FOX, Susan H et al.Progress in neuro-psychopharmacology & biological psychiatry. 2013, Vol 43, pp 151-156, issn 0278-5846, 6 p.Article

Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluationWADIA, Pettarusp M; TAN, Gamaliel; MUNHOZ, Renato P et al.Journal of neurology, neurosurgery and psychiatry. 2011, Vol 82, Num 4, pp 364-368, issn 0022-3050, 5 p.Article

The Selective Mu-Opioid Receptor Antagonist ADL5510 Reduces Levodopa-Induced Dyskinesia Without Affecting Antiparkinsonian Action in MPTP-Lesioned Macaque Model of Parkinson's DiseaseKOPRICH, James B; FOX, Susan H; JOHNSTON, Tom H et al.Movement disorders. 2011, Vol 26, Num 7, pp 1225-1233, issn 0885-3185, 9 p.Article